MedTrace Logo

Effect of Drospirenone-Ethinyl Estradiol (20microgram vs 30 Microgram) on Free Androgen Index in PCOS

NCT07318337 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-01-09

No results posted yet for this study

Summary

Combined hormonal contraceptive (CHC) improves androgen parameter in women with PCOS. High-dose CHC increases insulin resistance, whereas low dose CHC has minimal effects on carbohydrate metabolism. This quasi experimental study was conducted to compare the effects of Drospirenone-Ethinyl Estradiol (20µg) to that with Drospirenone-Ethinyl Estradiol (30µg) on free androgen index (FAI) in polycystic ovary syndrome. Medication was given for 3 months. FAI, HOMA-IR was measured in baseline and after treatment and results were compared.

Conditions

  • PCOS (Polycystic Ovary Syndrome)

Interventions

DRUG

Drospirenone Ethinyl Estradiol (20 microgram)

1tablet for consecutive 24 days followed by 4 days placebo for 3 months

DRUG

Drospirenone Ethinyl Estradiol (30 microgram)

once daily for 21 days followed by 7 days placebo for 3 months

Sponsors & Collaborators

  • Bangladesh Medical University

    collaborator OTHER

  • Mst.Sumyara Khatun

    lead OTHER

Principal Investigators

  • Shakeela Ishrat, FCPS · Bangladesh Medical University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-01
Primary Completion
2025-06-30
Completion
2025-06-30

Countries

  • Bangladesh

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07318337 on ClinicalTrials.gov